Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Protocol # 21-060


Active, not recruiting


This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.


  • Endometrial Neoplasms
  • Ovarian Cancer
  • Solid Tumor
  • Head and Neck Cancer


  • COM701 in combination with BMS-986207 and nivolumab.


Phase 1/Phase 2

Study Type


Further Study Details

Primary Outcome:

  • The proportion of subjects with adverse events on the study.
  • The proportion of subjects with adverse events in the 1st cycle during dose escalation within the DLT window (28 days).
  • The recommended dose for expansion (RDFE) of the combination.
  • The Area under the curve of COM701 in subjects receiving the 3-drug combination.

Secondary Outcome:

  • The objective response rate of subjects enrolled in cohorts 1-4.



Study Start Date

August 31, 2020


  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No


Compugen Ltd


Compugen Ltd

Official title

A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors. Identifier



Source: Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.